HyperMed Imaging
HyperMed develops advanced hyperspectral imaging devices for medical diagnostics, aiding in wound healing and amputation planning.
Founded
1997HyperMed develops advanced hyperspectral imaging devices for medical diagnostics, aiding in wound healing and amputation planning.
HyperMed Imaging, founded in 2006, focuses on developing advanced hyperspectral imaging devices for medical diagnostics. Their core mission is to enhance patient care through innovative imaging technology that provides detailed tissue oxygenation maps. The company's flagship product, OxyVu, received FDA 510(k) approval and is designed to aid in wound healing and amputation planning by measuring microvasculature perfusion. HyperMed targets the medical research and clinical diagnostics markets.
Notable figures associated with HyperMed include its pioneering team of engineers and medical professionals who have contributed to significant advancements in hyperspectral imaging. The company has secured FDA approval for its products and has been recognized in multiple clinical research publications for its effectiveness. HyperMed's impact lies in setting a new standard of care in medical diagnostics, improving patient outcomes through precise and non-invasive imaging solutions.
Companies similar to HyperMed Imaging include Spectrawave, O2M Technologies, Spectral Image and Hypervan.
HyperMed Imaging was founded in 1997.
HyperMed Imaging's headquarters is located in Memphis, TN, US.
HyperMed Imaging's most recent funding round was for $5M (USD) in April 2018.
As of Apr 4, 2018, HyperMed Imaging has disclosed funding of $10M (USD). Undisclosed round amounts are excluded.
HyperMed Imaging has 8 employees as of Feb 4, 2024.
Hypervan
hypervan.net
